药物排泄的可再吸收冠状动脉支架:对最近的进展进行了回顾
Lowie Vanoverbeke1, Johan Bennett1,2
1Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium.
Expert opinion on drug delivery
|April 16, 2025
概括
生物可吸收支架 (BRS) 为冠状动脉疾病提供了永久金属植入物的有希望的替代方案. 新的BRS显示出更好的安全性和有效性,特别是在患有简单病情的年轻患者中.
科学领域:
- 心血管医学 心血管医学
- 生物材料科学 生物材料科学
- 干预心脏病学 干预心脏病学
背景情况:
- 目前的药物排泄支架 (DES) 有持续的与设备相关的不良事件.
- 一种"不留任何东西"的方法旨在通过避免永久性金属植入物来实现卓越的临床结果.
- 生物吸收性支架 (BRS) 是一个新兴的脱技术.
研究的目的:
- 详细说明可用的生物吸收性支架的技术规格.
- 提供关于当前BRS器件的疗效和安全性的临床数据.
主要方法:
- 对当代BRS技术规范的审查.
- 对冠状动脉干预中BRS发表的临床试验数据的分析.
主要成果:
- 新的BRS具有更薄的支架和更生物相容的骨架 (聚合物或金属).
- 这些进步增强了辐射强度,加速了再吸收,并改善了抗血栓性质 (例如,基于的支架).
- BRS在治疗简单冠状动脉疾病方面表现出良好的临床疗效和安全性.
结论:
- 可生物吸收的支架在治疗冠状动脉疾病方面显著有前途.
- BRS技术的进步导致了生物相容性和安全性配置的改进.
- 预计BRS将发挥更为突出的作用,特别是在患有简单冠状动脉疾病的年轻患者中.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


